SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
49853Do they realize that nothing ever works in sepsis? :-)DewDiligence_on_SI14/7/2018
49852I have mentioned the Sepsis trial being run by Spectral Medical Inc. here now anSultan-4/7/2018
49851I have heard claims that some of their significant institutional investors (I asBiomaven14/7/2018
49850<There is some evidence to continue believing their CD47 program is best in cMiljenko Zuanic-4/6/2018
49849Looks like the only places to get serious up front money for CD47 R&D are thsemi_infinite -4/6/2018
49848Not big "real" dollars - I suspect TRIL could easily have gotten a deatuck-4/6/2018
49847Not big "real" dollars - I suspect TRIL could easily have gotten a deaBiomaven14/6/2018
49846TRIL > Boehringer, OSE tie up in I-O (CD47) deal that could total more than biocqr-4/5/2018
49845Likely both these RET drugs will work well. If I had to bet, I'd say the BPMBiomaven-4/4/2018
49844BPMC and LOXO both up strongly today. LOXO has data on it's RET drug at ASCOJamesK-4/4/2018
49843Thanks. I used to know that but forgot.Robohogs-4/3/2018
49842If you copy the title, google search the article name, and follow the link throumr.optimistic-4/2/2018
49841Although tafamidis is a pill for treating TTR cm, both hereditary and wild, I unArt Bechhoefer-4/2/2018
49840The market seems to agree with you regarding tafamidis and competition with AlnyA.J. Mullen-4/2/2018
49839Macrophages and cancer the-scientist.comBulbaMan24/1/2018
49838I bought $FB for a trade. All shares gone Friday by sale or call exercise. I aIRWIN JAMES FRANKEL-3/31/2018
49837tafamidis has some data in their 5.5 year study in neuropathy which showed slighJamesK13/30/2018
49836Pfizer's drug was previously rejected by the FDA based on a single study, buA.J. Mullen-3/30/2018
49835"When will PFE file for approval?" Beats me. I did some searching reArt Bechhoefer-3/30/2018
49834I replaced brakes around 190K. Only hybrids can have regenerative braking, and tdna_joe13/30/2018
49833I had a 2004 that looked brand new on the inside (not on the outside) after 150katticus4paws-3/30/2018
49832When will PFE file for approval "We look forward to sharing the detailed reJamesK-3/30/2018
49831There is a fraudulent conveyance suit regarding SCTY BTW.Robohogs-3/30/2018
49830TSLA IV higher than FGEN and BPMC. AMZN WAY up there too.Robohogs-3/30/2018
49829My 2005 Prius is at 207K miles. I am probably going to jinx it, but not a singledna_joe23/30/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News